Mammalian Display offers a proprietary technology enabling the construction of massive libraries of stable cell lines displaying human antibodies on their surface. As well as generating an abundance of therapeutic antibody leads, the technology also addresses “developability” issues early in discovery, thereby increasing the likelihood of successful progress through the development process. The platform uses gene editing technology to efficiently direct site-specific integration of antibody genes into a single locus within the mammalian cell genome. This enables construction of libraries of tens of millions of monoclonal stable cell lines displaying IgG-formatted antibodies on their surface. Using flow cytometry many millions of clones can be screened directly for high affinity and specificity. The technology can also identify and avoid clones with potential biophysical liabilities which could otherwise lead to costly delays or even product failure. As well as antibody discovery programs, the technology is suitable to chain shuffling and affinity maturation allowing the identification of antibodies with high affinities and/or improved developability profiles.
Features that differentiate mammalian display as an efficient technology for the isolation of mAb
|High throughput||Screening performed by FACS allowing for huge library sizes to be screened for binding and antibody presentation level|
|Selection as IgG||Full IgG antibodies displayed in surface of mammalian display thereby removing the need for IgG reformatting.|
|Selection in mammalian cell lines||Allows for mammalian post translational modifications within a mammalian cell background|
|Transcriptional normalisation||Site specific integration into a single locus allowing for comparative display analysis, higher display associates with better developability|
|Broad range of epitopes||Different strategies available to select for epitope specificity (high diversity)|
|Selection for affinity||Selection as IgG facilitates standard affinity measurements|